Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04927572




Registration number
NCT04927572
Ethics application status
Date submitted
2/06/2021
Date registered
16/06/2021
Date last updated
31/08/2022

Titles & IDs
Public title
Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis
Scientific title
A Phase I/IIa Randomized, Double-Blind, Vehicle-Controlled Clinical Trial With Separate Open-Label Active Treatment Phase Evaluating the Safety, Pharmacokinetics and Efficacy of FMX114 Gel in the Treatment of Mild-to-Moderate Atopic Dermatitis in Adults
Secondary ID [1] 0 0
VY2021-01
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Atopic Dermatitis 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - FMX114
Other interventions - Vehicle

Experimental: FMX114 -

Placebo Comparator: Vehicle -


Treatment: Drugs: FMX114
Active Comparator

Other interventions: Vehicle
Placebo Comparator
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Mean Change from Baseline in Atopic Dermatitis Severity Index (ADSI) score at Day 29
Timepoint [1] 0 0
Day 29
Primary outcome [2] 0 0
Incidence, type and severity of adverse events (AEs) at Day 43
Timepoint [2] 0 0
Day 43

Eligibility
Key inclusion criteria
1. Subjects must have the ability to understand and be willing to sign an informed
consent form.

2. Aged = 18 years, at time of screening visit.

3. Weight = 40 kg, at time of screening visit.

4. Diagnosis of Atopic Dermatitix with a total body surface area (BSA) of AD involvement
of = 35% excluding involvement of face, scalp and groin at screening and Day 1, prior
to first dose.

5. Atopic dermatitis should be present for at least 3 months with stable disease for = 1
month at the time of the screening visit and on Day 1, prior to dose administration.

6. Have the presence of at least 2 comparable target AD lesions (size approximately 10 to
200 cm2), located on the trunk, upper extremities or lower extremities. In addition,
the 2 target lesions:

1. must have ADSI score of = 6 and = 12 AND a between-lesion difference in ADSI of =
1.

2. must be separated by = 10 cm.

7. Positive varicella zoster virus (VZV) antibody test at the screening visit. At the
discretion of the Investigator, subjects who return a negative result may be
re-screened following a full VZV vaccination course.

8. Medically healthy in the opinion of the Investigator without significant abnormalities
at the screening visit and prior to dose administration on Day 1, including:

1. Physical examination without any clinically relevant findings (excluding findings
relating to AD).

2. Systolic blood pressure in the range of 90 to 160 mmHg (inclusive) and diastolic
blood pressure in the range of 50 to 95 mmHg (inclusive) after 5 minutes in
supine position.

3. Heart rate in the range of 45 to 100 bpm (inclusive) after 5 minutes rest in
supine.

4. Body temperature (tympanic or oral), between 35.5°C and 37.7°C (inclusive).

5. Electrocardiogram findings (ventricular HR, PR interval, QRS duration, QT
interval and QTcF) within normal ranges (site-specific normal ranges may be
used).

6. Triplicate 12-lead electrocardiogram (ECG) (taken after the subject has been
supine for at least 5 minutes) with a QTcF = 450 msec for males and = 470 msec
for females and no other clinically significant abnormalities.

7. All laboratory blood and urinalysis test results within normal ranges for the
local laboratory, including the following specific findings:

i. Lymphocyte count = 0.5 x 10 9/L ii. Haemoglobin = 9g/dL iii. Absolute neutrophil
count = 1 x 10 9/L Assessments may be repeated once, if abnormal values were recorded
in the first instance, at the discretion of the PI.

9. Female subjects must:

- Be of non-childbearing potential (i.e., surgically sterilised [hysterectomy,
bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before the
screening visit]) or postmenopausal (where postmenopausal is defined as no menses
for 12 months without an alternative medical cause, and a follicle-stimulating
hormone [FSH] level >40 IU/L at the screening visit), or

- If of childbearing potential, must agree not to donate ova, not to attempt to
become pregnant and, if engaging in sexual intercourse with a male partner, must
agree to use an acceptable method of contraception (refer to Section 21.5) from
signing the consent form until at least 2 months after the last dose of the study
drug.

10. Male subjects, if not biologically or surgically sterilized, must agree not to donate
sperm and, if engaging in sexual intercourse, must agree to use a condom from signing
the consent form until at least 90 days after the last dose of study drug. If engaging
with a female partner who could become pregnant, the female partner must additionally
use an acceptable method of contraception (refer to Section 21.5) for this same
period.

11. Have suitable venous access for blood sampling.

12. Be willing and able to comply with all study assessments (optional photography
assessments excluded) and adhere to the protocol schedule and restrictions
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. In the opinion of the Investigator, subject has unstable or actively infected AD at
the screening visit, or prior to dose administration on Day 1.

2. Active impetigo at any of the target lesions.

3. Concomitant dermatologic conditions (e.g. irritant contact dermatitis, allergic
contact dermatitis, psoriasis, etc.) or other medical condition(s) which may, in the
opinion of the Investigator, interfere with evaluations of the subject's response to
study drug.

4. Positive test results for active human immunodeficiency virus (HIV-1 or HIV-2),
hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies at the
screening visit.

5. Evidence or history of active, latent or inadequately treated tuberculosis (TB)
infection at the screening visit.

6. Evidence or history of disseminated or recurrent herpes zoster infection.

7. Clinically significant active infection (in the opinion of the Investigator) within 2
weeks prior to first dose application on Day 1.

8. Any known or suspected premalignant or malignant disease within the last 5 years
(excluding successfully treated basal cell carcinomas).

9. Have received AD-directed therapy within the following timeframes prior to dose
administration on Day 1:

1. Ultraviolet A (UVA) or Ultraviolet B (UVB) therapy within 2 weeks.

2. Systemic or topical corticosteroids within the past 2 weeks.

3. Other topical anti-inflammatory therapy e.g. Janus kinase (JAK) inhibitors,
calcineurin inhibitors, Phosphodiesterase-4 inhibitors within the past 2 weeks.

4. Systemic JAK inhibitors within the past 12 weeks.

5. Systemic biologic therapy within the past 12 weeks.

6. Bleach or other antiseptic baths (e.g., potassium permanganate) within the past 2
weeks.

7. Any other active topical therapy on target lesions within 7 days (does not
include non-medicated moisturisers, sunscreens, lotions or creams).

10. Use of any topical product (e.g. sunscreen, lotions, creams) on the target lesion
within 24 hours prior to dose administration on Day 1.

11. Live and live attenuated vaccines are not permitted within 30 days prior to the first
application of study drug, and for 2 months following the last dose application. It is
noted that mRNA or adeno-associated virus (AAV)-based COVID-19 vaccinations are
permitted at any stage throughout the study.

12. Use of any systemically absorbed prescription or over-the-counter medication
(including herbal products, diet aids, and hormone supplements) within 10 days or 5
half-lives of the medication (whichever is longer) prior to the first study drug
administration Exceptions may be made for medications which, in the opinion of the
Investigator, are unlikely to affect the course of the AD during the study period (for
example stable use of antihistamines for asthma or allergies. Antibiotics, if not
known to impact AD disease course, may also be allowed at the discretion of the PI in
consultation with the medical monitor).

13. Participation in another investigational clinical trial within 30 days (or 5
half-lives, of the investigational agent) (whichever is longer) prior to the first
study drug administration.

14. Presence or evidence of recent sunburn, scar tissue, tattoo (more than 25% of body
area), open sore, or branding that, in the opinion of the Investigator, would
interfere with evaluations of the subject's response to study drug.

15. Known hypersensitivity to any component of the study drug.

16. Demonstrated clinically significant (required intervention, e.g., emergency room
visit, epinephrine administration) allergic reactions (e.g., food, drug, or atopic
reactions, asthmatic episodes) which, in the opinion of the Investigator, would
interfere with the subject's ability to participate in the trial.

17. Known or suspected history of alcohol or drug abuse (in the opinion of the
Investigator) within the last 2 years.

18. Documented history of depression or self-harm that is not, in the opinion of the
Investigator, currently adequately controlled with medication or in remission.

19. Positive drug or alcohol test results at the screening visit or on Day 1, prior to
dose administration (may be repeated once, if a positive test was recorded in the
first instance, at the discretion of the Investigator).

20. Consumption of grapefruit or Seville orange (or products containing grapefruit or
Seville orange) within 72 hours prior to the first FMX114 dose administration on Day 1
(consumption is also not permitted throughout the duration of the study).

21. Any other condition or prior therapy that in the opinion of the Investigator would
make the subject unsuitable for this study, including inability to cooperate fully
with the requirements of the study protocol or likelihood of noncompliance with any
study requirements

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
13/10/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
9/08/2022
Sample size
Target
Accrual to date
Final
21
Recruitment in Australia
Recruitment state(s)
ACT,NSW,SA
Recruitment hospital [1] 0 0
Investigator #5 - Phillip
Recruitment hospital [2] 0 0
Investigator #6 - Darlinghurst
Recruitment hospital [3] 0 0
Investigational Site #1 - Adelaide
Recruitment postcode(s) [1] 0 0
2606 - Phillip
Recruitment postcode(s) [2] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
United States of America
State/province [2] 0 0
Pennsylvania

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Vyne Therapeutics Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A Phase I/IIa Randomized, Double-Blind, Vehicle-Controlled Clinical Trial with Separate
Open-Label Active Treatment Phase Evaluating the Safety, Pharmacokinetics and Efficacy of
FMX114 Gel in the Treatment of Mild-to-Moderate Atopic Dermatitis in Adults
Trial website
https://clinicaltrials.gov/ct2/show/NCT04927572
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04927572